Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients

Katica Cvitkusic Lukenda, Ana Cipak Gasparovic, Mirta Milic, Barbara Radovani, Frano Vuckovic, Jelena Jakab, Domagoj Vucic, Ana Kovacevic, Ivan Gudelj · 2026

Read Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients by Katica Cvitkusic Lukenda, Ana Cipak Gasparovic, Mirta Milic, Barbara Radovani, Frano Vuckovic, Jelena Jakab, Domagoj Vucic, Ana Kovacevic, Ivan Gudelj (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13277242.txt.

Description

Katica Cvitkusic Lukenda leads a 2026 trial of a diabetes drug given once before a heart artery imaging test. The test uses dye and radiation that can cause oxidative stress, meaning damage from reactive oxygen. Sixty patients without diabetes were assigned to standard care or to empagliflozin two hours before the planned procedure.

Blood tests over the next day showed less oxidative DNA damage in the drug group and steadier antioxidant defenses. Sugar patterns on immune proteins also shifted toward a less inflammatory profile, though some changes were not firm after strict checks. A single dose may protect vessels during the test, the authors say, while calling for larger trials to confirm it.

Catalog record

CREATORKatica Cvitkusic Lukenda, Ana Cipak Gasparovic, Mirta Milic, Barbara Radovani, Frano Vuckovic, Jelena Jakab, Domagoj Vucic, Ana Kovacevic, Ivan Gudelj
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38782
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13277242

Browse the full library · About the Tower of Babel